Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibiotic exposure in culture-negative preterm infants: a 10-year single-centre study.

Pediatric research·2026

Same author

Epidemiology and Outcomes of Neonatal Sepsis: Experience from a Tertiary Australian NICU.

Neonatology·2024

Same author

Neonatal Staphylococcus Aureus Sepsis: a 20-year Western Australian experience.

Journal of perinatology : official journal of the California Perinatal Association·2022

Same author

Effect of cumulative dexamethasone dose in preterm infants on neurodevelopmental and growth outcomes: a Western Australia experience.

Archives of disease in childhood. Fetal and neonatal edition·2020

Same author

Breastfeeding and lithium: is breast always best?

The lancet. Psychiatry·2018

Same author

Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling.

International journal of antimicrobial agents·2017

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect

A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect

Published on: September 22, 2023

Gabapentin and breastfeeding: a case report.

Judith H Kristensen¹, Kenneth F Ilett, L Peter Hackett

¹Department of Pharmacy at the Women's and Children's Health Service, Subiaco, Western Australia.

Journal of Human Lactation : Official Journal of International Lactation Consultant Association

|October 26, 2006

Summary

This study measured gabapentin levels in breast milk, finding low infant exposure (2.34% relative infant dose). The infant showed no adverse effects, supporting cautious gabapentin use in breastfeeding mothers.

Related Experiment Videos

Last Updated: Jul 19, 2026

A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect

A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect

Published on: September 22, 2023

Area of Science:

Pharmacology
Neonatal Studies
Maternal-Fetal Medicine

Background:

Gabapentin is frequently prescribed, necessitating understanding of its transfer into breast milk.
Assessing infant exposure is crucial for safe breastfeeding practices during maternal medication use.

Observation:

A single mother-infant pair was studied over 24 hours at steady-state gabapentin dosage.
Gabapentin concentrations in milk and plasma were quantified using high-performance liquid chromatography.
Infant exposure was calculated based on milk concentration, estimated milk production, and maternal dosage.

Findings:

The milk-plasma ratio of gabapentin was determined to be 0.86.
The relative infant dose was calculated at 2.34%, with absolute infant dose around 3% of pediatric recommendations.
Infant plasma gabapentin levels were approximately 6% of maternal levels, with no observed adverse effects.

Implications:

These findings suggest limited infant exposure to gabapentin via breastfeeding.
Gabapentin may be considered for breastfeeding mothers following a thorough individual risk-benefit assessment.
Further research with larger cohorts is warranted to confirm these observations.